2021 ICD-10-CM Diagnosis Code C95

Leukemia of unspecified cell type

    2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
  • C95 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2021 edition of ICD-10-CM C95 became effective on October 1, 2020.
  • This is the American ICD-10-CM version of C95 - other international versions of ICD-10 C95 may differ.
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C95. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • personal history of leukemia (
    ICD-10-CM Diagnosis Code Z85.6

    Personal history of leukemia

      2016 2017 2018 2019 2020 2021 Billable/Specific Code POA Exempt
    Applicable To
    • Conditions classifiable to C91-C95
    Type 1 Excludes
    Z85.6
    )
The following code(s) above C95 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C95:
  • C00-D49
    2021 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C81-C96
    2021 ICD-10-CM Range C81-C96

    Malignant neoplasms of lymphoid, hematopoietic and related tissue

    Type 2 Excludes
    • Kaposi's sarcoma of lymph nodes (C46.3)
    • secondary and unspecified neoplasm of lymph nodes (C77.-)
    • secondary neoplasm of bone marrow (C79.52)
    • secondary neoplasm of spleen (C78.89)
    Malignant neoplasms of lymphoid, hematopoietic and related tissue
Clinical Information
  • (loo-kee-mee-a) cancer of blood-forming tissue.
  • A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.
  • A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (from the merck manual, 2006)
  • A progressive, proliferative disease of blood cells, originating from myeloid or lymphoid stem cells.
  • Cancer that starts in blood-forming tissue such as the bone marrow and causes large numbers of blood cells to be produced and enter the bloodstream.
  • Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work.there are different types of leukemia, including
    • acute lymphocytic leukemia
    • acute myeloid leukemia
    • chronic lymphocytic leukemia
    • chronic myeloid leukemia
    leukemia can develop quickly or slowly. Chronic leukemia grows slowly. In acute leukemia, the cells are very abnormal and their number increases rapidly. Adults can get either type; childen with leukemia most often have an acute type.some leukemias can often be cured. Other types are hard to cure, but you can often control them. Treatments may include chemotherapy, radiation and stem cell transplantation. Even if symptoms disappear, you might need therapy to prevent a relapse. nih: national cancer institute
  • Progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow; classified according to degree of cell differentiation as acute or chronic, and according to predominant type of cell involved as myelogenous or lymphocytic.
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
Code annotations containing back-references to C95:
  • Type 1 Excludes: D72.825
    ICD-10-CM Diagnosis Code D72.825

    Bandemia

      2016 2017 2018 2019 2020 2021 Billable/Specific Code
    Applicable To
    • Bandemia without diagnosis of specific infection
    Type 1 Excludes
ICD-10-CM Codes Adjacent To C95
C94.32 …… in relapse
C94.4 Acute panmyelosis with myelofibrosis
C94.40 …… not having achieved remission
C94.41 …… in remission
C94.42 …… in relapse
C94.6 Myelodysplastic disease, not classified
C94.8 Other specified leukemias
C94.80 …… not having achieved remission
C94.81 …… in remission
C94.82 …… in relapse
C95 Leukemia of unspecified cell type
C95.0 Acute leukemia of unspecified cell type
C95.00 …… not having achieved remission
C95.01 …… in remission
C95.02 …… in relapse
C95.1 Chronic leukemia of unspecified cell type
C95.10 …… not having achieved remission
C95.11 …… in remission
C95.12 …… in relapse
C95.9 Leukemia, unspecified
C95.90 …… not having achieved remission

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.